Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00134238|
Recruitment Status : Terminated
First Posted : August 24, 2005
Last Update Posted : February 17, 2012
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with mixed hyperlipidemia
|Condition or disease||Intervention/treatment||Phase|
|Mixed Hyperlipidemia||Drug: torcetrapib/atorvastatin Drug: atorvastatin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||755 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia|
|Study Start Date :||November 2003|
|Actual Primary Completion Date :||December 2006|
|Actual Study Completion Date :||December 2006|
- Change in intima media thickness as measured by carotid ultrasound
- Changes in levels of lipids and other biomarkers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00134238
Show 51 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|